FDA grants Orphan Drug Designation to iadademstat in SCLC

FDA Center for Drug Evaluation and Research is soliciting grant applications from independent organizations to support meetings that bring together a broad range of stakeholders to explore, research, and address issues related to medical products, policy, and surveillance methods and systems.

April 19, 2024

Vol.50 No.16

Clinical Roundup

CAP publishes guideline for PD-L1 testing for lung cancer

The College of American Pathologists in collaboration with the International Association for the Study of Lung Cancer, Pulmonary Pathology Society, Association for Molecular Pathology, and the LUNGevity Foundation have developed evidence-based recommendations for the testing of immunotherapy biomarkers, including programmed cell death ligand-1 and tumor mutation burden in patients with non-small cell lung carcinoma.

April 19, 2024

Vol.50 No.16

Drugs & Targets

FDA approves Alecensa for ALK-positive early-stage lung cancer

FDA approved Alecensa (alectinib) for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer (tumors ≥ 4 cm or node positive), as detected by an FDA-approved test.

April 19, 2024

Vol.50 No.16

Drugs & Targets

FDA approves Lumisight to assist breast cancer detection

FDA approved Lumisight (pegulicianine) in adults with breast cancer to assist the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery.

April 19, 2024

Vol.50 No.16

FDA grants Orphan Drug Designation to iadademstat in SCLC

YOU MAY BE INTERESTED IN

Surviving lung cancer focused Morhaf Al Achkar’s career on addressing health disparities

Tobacco in the tabloids: How the Weekly World News covered smoking for laughs—and the National Enquirer wouldn’t cover it at all

FDA offers funding for meetings on medical policy activities

CAP publishes guideline for PD-L1 testing for lung cancer

FDA approves Alecensa for ALK-positive early-stage lung cancer

FDA approves Lumisight to assist breast cancer detection

Renew today!

Subscriber content

Login